Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 622-631

  Zarzuelo, María José ^a   Gómez Guzmán, Manuel ^a   Jiménez, Rosario ^a,b   Quintela, Ana María ^a   Romero, Miguel ^a   Sánchez, Manuel ^a   Zarzuelo, Antonio ^a,c   Tamargo, Juan ^d   Pérez Vizcaíno, Francisco ^d,e,f   Duarte, Juan ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Institute of Neurosciences   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

DOCA salt hypertension; Endothelial dysfunction; Endothelin 1; PPAR ; Regulators of G protein coupled signalling proteins

Indexed keywords

3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ACETYLCHOLINE; CATALASE; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN; G PROTEIN COUPLED SIGNALLING PROTEIN 5; GLUTATHIONE PEROXIDASE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTAGLANDIN F2; PROTEIN P22; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION; URINE LEVEL; VASODILATATION;

DOCA-SALT HYPERTENSION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIN-1; PPARΒ/Δ; REGULATORS OF G PROTEIN-COUPLED SIGNALLING PROTEINS;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE ACETATE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HYPERTENSION; NADPH OXIDASE; PPAR-BETA; RATS; REACTIVE OXYGEN SPECIES; RGS PROTEINS; THIAZOLES; VASODILATION;

EID: 84883245464     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt152     Document Type: Article

References (44)

1. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997;96:3264-3265.
2. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
3. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-14488.
4. WuR, Millette E,WuL, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001;19:741-748.
5. Beswick RA, Dorrance AM, Leite R,Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001;38: 1107-1111.
6. Jiménez R, López-Sepúlveda R, Kadmiri M, Romero M, Vera R, SánchezMet al. Polyphenols restore endothelial function in DOCA-salt hypertension: role of endothelin-1 and NADPH oxidase. Free Radic Biol Med 2007;43:462-473.
7. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, KossM, Cote LJ et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975;36:300-309.
8. Letizia C, Cerci S, De Toma G, D'Ambrosio C, De Ciocchis A, Coassin S et al. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hypertension. J Hum Hypertens 1997;11:447-451.
9. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 2001;103:263-268.
10. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003;107:1053-1058.
11. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94.
12. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94: 1168-1178.
13. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, DiepQNet al. Peroxisome proliferatoractivated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003;42:737-743.
14. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and-gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003;23:45-51.
15. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004;43:1481-1488.
16. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res 2005;579:163-171.
17. Zhou Y, Luo P, Chang HH, Huang H, Yang T, Dong Z et al. Clofibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int 2008;74: 1040-1048.
18. Bae EH, Kim IJ, Ma SK, KimSW. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats. Hypertens Res 2010;33:255-262.
19. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
20. Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002;40:822-831.
21. Montezano AC, Amiri F, Tostes RC, Touyz RM, Schiffrin EL. Inhibitory effects of PPARgamma onendothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. J Am Soc Hypertens 2007;1:150-160.
22. Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 2004;109:904-910.
23. Huang Y, Zhang H, Shao Z, O'Hara KA, Kopilas MA, Yu L et al. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta. Cardiovasc Res 2011;90:267-275.
24. Lee CH, Chawla A, Urbiztondo N, Liao D, BoisvertWA, Evans RM et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003;302: 453-457.
25. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005;181:29-37.
26. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH et al. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 2008;105:4277-4282.
27. Zarzuelo MJ, Jiménez R, Galindo P, Sánchez M, Nieto A, Romero M et al. Antihypertensive effects of peroxisome proliferator-activated receptor-b activation in spontaneously hypertensive rats. Hypertension 2011;58:733-743.
28. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol Ther 2007;116:473-495.
29. Ketsawatsomkron P, Lorca RA, Keen HL,Weatherford ET, Liu X, Pelham CJ et al. PPARg regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res 2012;111:1446-1458.
30. Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Müller- Brüsselbach S, Müller R. Transcriptional profiling identifies functional interactions of TGF b and PPAR b/d signaling: synergistic induction of ANGPTL4 transcription. J Biol Chem 2010;285: 29469-29479.
31. Meissner M, Berlinski B, Doll M, Hrgovic I, Laubach V, Reichenbach G et al. AP1-dependent repression of TGFa-mediated MMP9 upregulation by PPARd agonists in keratinocytes. Exp Dermatol 2011;20:425-429.
32. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994;24:183-188.
33. Jiang B, Liang P, Zhang B, Huang X, Xiao X. Enhancement of PPAR-beta activity by repetitive low-grade H(2)O(2) stress protectshuman umbilical vein endothelial cells from subsequent oxidative stress-induced apoptosis. Free Radic Biol Med 2009;46:555-563.
34. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, HeimMet al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001;15:3263-3277.
35. Kim B, Kim J, Bae YM,ChoSI,KwonSC, Jung JY et al. p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats. Hypertension 2004;43:1086-1091.
36. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, PengNet al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003;111: 445-452.
37. Bondjers C, Kalén M, Hellström M, Scheidl SJ, Abramsson A, RennerO et al. Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol 2003;162:721-729.
38. Chang YP, Liu X, Kim JD, Ikeda MA, Layton MR, Weder AB et al. Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet 2007;80: 253-264.
39. Wang X, Adams LD, Pabón LM, MahoneyWMJr, Beaudry D, Gunaje J et al. RGS5, RGS4, and RGS2 expression and aortic contractibility are dynamically co-regulated during aortic banding-induced hypertrophy. J Mol Cell Cardiol 2008;44:539-550.
40. Callera GE, Tostes RC, Yogi A, MontezanoAC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 2006;110:243-253.
41. Kim HJ, Ham SA, Paek KS, Hwang JS, Jung SY, KimMYet al. Transcriptional up-regulation of antioxidant genes by PPARd inhibits angiotensin II-induced premature senescence in vascular smooth muscle cells. Biochem Biophys Res Commun 2011;406:564-569.
42. Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 2006;69:440-449.
43. Jiménez R, Sánchez M, Zarzuelo MJ, Romero M, Quintela AM, López-Sepúlveda R et al. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. J Pharmacol Exp Ther 2010;332:554-561.
44. Harrington LS, Moreno L, Reed A,Wort SJ, Desvergne B, GarlandCet al. The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One 2010;5:e9526.